10 December 2016 - The latest wrinkle in the fight against rising drug prices involves insurers and pharmacy benefit managers asking drug makers to accept lower prices for the latest medicines emerging from their labs when they don't achieve the desired results.
Insurers like Aetna, Cigna and Harvard Pilgrim Health Care, as well as pharmacy benefit managers such as Express Scripts, are engaging major manufacturers including Novartis, Merck and Astra Zeneca in these risk-based deals because many of the latest blockbusters drugs are lacking long-term benefits data.